Creative Medical Technology Holdings, Inc. SEC filings CELZ
Creative Medical Technology Holdings, Inc. has 409 filings in SEC EDGAR's recent list, going back to Sep 13, 2002. Its latest annual report, Form 10-K, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 25, 2026 (material agreement, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13D | Ownership over 5% (active) | Oct 1, 2026 | — |
| 4 | Insider transaction | Sep 25, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 25, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Aug 31, 2026 | Aug 28, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 424B3 | Prospectus | Aug 3, 2026 | — |
| EFFECT | Filing | Jul 31, 2026 | — |
| S-3 | Shelf registration | Jul 24, 2026 | — |
| DEF 14A | Proxy statement | Jul 14, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
Jul 2, 2026 | Jun 30, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 1, 2026 | Jul 1, 2026 |
| RW | Filing | Jun 30, 2026 | — |
| S-1/A | Amended registration statement | Jun 26, 2026 | — |
| S-1 | Registration statement | Jun 25, 2026 | — |
| DRS | Filing | May 28, 2026 | — |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 24, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 20, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Dec 31, 2025 | Dec 26, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Dec 19, 2025 | Dec 18, 2025 |
| 424B3 | Prospectus | Dec 16, 2025 | — |
| EFFECT | Filing | Dec 12, 2025 | — |
| CORRESP | Letter to the SEC | Dec 9, 2025 | — |
| S-3 | Shelf registration | Nov 21, 2025 | — |
| DEF 14A | Proxy statement | Nov 13, 2025 | Dec 26, 2025 |
| 8-K |
Current report
Officer or director change
|
Nov 12, 2025 | Nov 6, 2025 |
| 10-Q | Quarterly report | Nov 7, 2025 | Sep 30, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 3, 2025 | Nov 3, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 31, 2025 | Oct 29, 2025 |
| DEF 14A | Proxy statement | Oct 30, 2025 | Oct 27, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| 10-Q | Quarterly report | Aug 8, 2025 | Jun 30, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2025 | — |
| 10-Q | Quarterly report | May 9, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 6, 2025 | May 5, 2025 |
| 10-K/A | Amended annual report | Apr 25, 2025 | Dec 31, 2024 |
| 424B3 | Prospectus | Apr 15, 2025 | — |
| EFFECT | Filing | Apr 11, 2025 | — |
| 8-K |
Current report
Listing notice
|
Apr 11, 2025 | Apr 8, 2025 |
| CORRESP | Letter to the SEC | Apr 9, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2025 | — |
| 10-K/A | Amended annual report | Apr 4, 2025 | Dec 31, 2024 |
| S-3 | Shelf registration | Apr 2, 2025 | — |
| 10-K/A | Amended annual report | Mar 19, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Mar 17, 2025 | Mar 19, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 14, 2025 | Mar 10, 2025 |
| 10-K | Annual report | Mar 14, 2025 | Dec 31, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 7, 2025 | Mar 7, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 7, 2025 | Mar 6, 2025 |
| 4 | Insider transaction | Feb 20, 2025 | Feb 18, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Dec 26, 2024 | Dec 19, 2024 |
| 424B3 | Prospectus | Nov 20, 2024 | — |
| EFFECT | Filing | Nov 19, 2024 | — |
| CORRESP | Letter to the SEC | Nov 15, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2024 | — |
| 10-Q | Quarterly report | Nov 8, 2024 | Sep 30, 2024 |
| S-1 | Registration statement | Nov 8, 2024 | — |
| DEF 14A | Proxy statement | Nov 4, 2024 | Dec 19, 2024 |
| PRER14A | Prer 14a | Oct 23, 2024 | — |
| 8-K |
Current report
Material agreement
|
Oct 23, 2024 | Oct 22, 2024 |
| 424B5 | Prospectus supplement | Oct 23, 2024 | — |
| EFFECT | Filing | Oct 15, 2024 | — |
| CORRESP | Letter to the SEC | Oct 10, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 10, 2024 | — |
| PRE 14A | Preliminary proxy statement | Oct 4, 2024 | Oct 4, 2024 |
| S-3 | Shelf registration | Oct 4, 2024 | — |
| 10-Q | Quarterly report | Aug 9, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jul 25, 2024 | Jul 19, 2024 |
| DEF 14A | Proxy statement | Jun 5, 2024 | Jul 19, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
May 17, 2024 | May 14, 2024 |
| PRE 14A | Preliminary proxy statement | May 17, 2024 | Jul 19, 2024 |
| 10-Q | Quarterly report | May 10, 2024 | Mar 31, 2024 |
| 10-K/A | Amended annual report | Apr 29, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Mar 22, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Dec 20, 2023 | Dec 20, 2023 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| DEF 14A | Proxy statement | Nov 3, 2023 | Oct 31, 2023 |
| 10-Q | Quarterly report | Aug 11, 2023 | Jun 30, 2023 |
| 4 | Insider transaction | Jun 29, 2023 | Jun 27, 2023 |
| 8-K |
Current report
Other events
|
Jun 28, 2023 | Jun 27, 2023 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Jun 9, 2023 | Jun 9, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | May 26, 2023 | — |
| 10-Q | Quarterly report | May 12, 2023 | Mar 31, 2023 |
| SC 13G | Ownership over 5% (passive) | May 2, 2023 | — |
| 10-K/A | Amended annual report | May 1, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 31, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Dec 19, 2022 | Dec 19, 2022 |
| 4 | Insider transaction | Nov 23, 2022 | Nov 21, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| DEF 14A | Proxy statement | Oct 26, 2022 | Oct 25, 2022 |
| 4 | Insider transaction | Sep 29, 2022 | Sep 27, 2022 |
| 4 | Insider transaction | Sep 28, 2022 | Sep 27, 2022 |
| 4 | Insider transaction | Sep 22, 2022 | Sep 21, 2022 |
| 10-Q | Quarterly report | Aug 12, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Listing notice
|
Jul 14, 2022 | Jul 8, 2022 |
| 4 | Insider transaction | Jun 14, 2022 | Jun 14, 2022 |
| 4 | Insider transaction | Jun 7, 2022 | Jun 6, 2022 |
| 4 | Insider transaction | May 20, 2022 | May 20, 2022 |
| 424B3 | Prospectus | May 20, 2022 | — |
| EFFECT | Filing | May 19, 2022 | — |
| CORRESP | Letter to the SEC | May 17, 2022 | — |
| UPLOAD | Letter from the SEC | May 16, 2022 | — |
| 10-Q | Quarterly report | May 13, 2022 | Mar 31, 2022 |
| S-3 | Shelf registration | May 10, 2022 | — |
| D | Filing | May 5, 2022 | — |
| RW | Filing | May 4, 2022 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
May 4, 2022 | Apr 29, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
May 4, 2022 | Apr 29, 2022 |
| 10-K/A | Amended annual report | Apr 29, 2022 | Dec 31, 2021 |
| S-1 | Registration statement | Apr 22, 2022 | — |
| 10-K | Annual report | Mar 30, 2022 | Dec 31, 2021 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2022 | — |
| 4 | Insider transaction | Feb 11, 2022 | Feb 9, 2022 |
| 4 | Insider transaction | Feb 11, 2022 | Feb 9, 2022 |
| 8-K |
Current report
Officer or director change
|
Feb 11, 2022 | Feb 9, 2022 |
| 3 | Initial insider ownership | Jan 5, 2022 | Dec 2, 2021 |
| SC 13G | Ownership over 5% (passive) | Dec 20, 2021 | — |
| 3 | Initial insider ownership | Dec 13, 2021 | Dec 2, 2021 |
| 3 | Initial insider ownership | Dec 13, 2021 | Dec 2, 2021 |
| SC 13G | Ownership over 5% (passive) | Dec 10, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Dec 8, 2021 | — |
| 8-K |
Current report
Material agreement, Listing notice, Officer or director change
|
Dec 7, 2021 | Dec 3, 2021 |
| 424B4 | Prospectus | Dec 6, 2021 | — |
| EFFECT | Filing | Dec 2, 2021 | — |
| CERT | Filing | Dec 2, 2021 | — |
| 8-A12B | Filing | Dec 2, 2021 | — |
| CORRESP | Letter to the SEC | Dec 2, 2021 | — |
| S-1/A | Amended registration statement | Dec 2, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 2, 2021 | — |
| S-1/A | Amended registration statement | Dec 1, 2021 | — |
| CORRESP | Letter to the SEC | Nov 30, 2021 | — |
| CORRESP | Letter to the SEC | Nov 30, 2021 | — |
| CORRESP | Letter to the SEC | Nov 23, 2021 | — |
| S-1/A | Amended registration statement | Nov 23, 2021 | — |
| 10-Q | Quarterly report | Nov 15, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Nov 9, 2021 | Nov 8, 2021 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Nov 5, 2021 | Nov 2, 2021 |
| UPLOAD | Letter from the SEC | Oct 7, 2021 | — |
| S-1 | Registration statement | Sep 28, 2021 | — |
| DEF 14C | Information statement | Sep 24, 2021 | Sep 20, 2021 |
| 8-K |
Current report
Officer or director change
|
Sep 22, 2021 | Sep 16, 2021 |
| PRE 14C | Filing | Sep 7, 2021 | Sep 7, 2021 |
| D | Filing | Aug 27, 2021 | — |
| 10-Q | Quarterly report | Aug 16, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Aug 12, 2021 | Aug 9, 2021 |
| 4 | Insider transaction | Jul 22, 2021 | Jul 20, 2021 |
| 4 | Insider transaction | Jul 16, 2021 | Jul 15, 2021 |
| 4 | Insider transaction | Jul 16, 2021 | Jul 15, 2021 |
| 4 | Insider transaction | Jul 16, 2021 | Jul 15, 2021 |
| 4 | Insider transaction | Jun 29, 2021 | Jun 28, 2021 |
| 10-Q | Quarterly report | May 17, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Apr 2, 2021 | Mar 30, 2021 |
| 8-K |
Current report
Other events
|
Mar 25, 2021 | Mar 23, 2021 |
| 10-K | Annual report | Mar 17, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Mar 12, 2021 | Mar 11, 2021 |
| 8-K |
Current report
Other events
|
Mar 5, 2021 | Mar 3, 2021 |
| 8-K |
Current report
Other events
|
Feb 22, 2021 | Feb 16, 2021 |
| 8-K/A |
Amended current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Feb 22, 2021 | Feb 12, 2021 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Feb 18, 2021 | Feb 12, 2021 |
| 8-K |
Current report
Other events
|
Feb 12, 2021 | Feb 8, 2021 |
| 8-K |
Current report
Other events
|
Feb 8, 2021 | Feb 1, 2021 |
| 8-K |
Current report
Other events
|
Jan 14, 2021 | Jan 12, 2021 |
| 4 | Insider transaction | Jan 8, 2021 | Jan 8, 2021 |
| 4 | Insider transaction | Jan 8, 2021 | Jan 8, 2021 |
| 8-K |
Current report
Other events
|
Jan 4, 2021 | Dec 22, 2020 |
| 4 | Insider transaction | Dec 31, 2020 | Dec 28, 2020 |
| 4 | Insider transaction | Dec 31, 2020 | Dec 28, 2020 |
| 4 | Insider transaction | Dec 31, 2020 | Dec 28, 2020 |
| 10-Q | Quarterly report | Nov 13, 2020 | Sep 30, 2020 |
| 4 | Insider transaction | Oct 2, 2020 | Sep 30, 2020 |
| 4 | Insider transaction | Oct 2, 2020 | Sep 30, 2020 |
| 10-Q | Quarterly report | Aug 14, 2020 | Jun 30, 2020 |
| 4 | Insider transaction | Jun 5, 2020 | Jun 3, 2020 |
| 4 | Insider transaction | Jun 5, 2020 | Jun 3, 2020 |
| 10-Q | Quarterly report | May 15, 2020 | Mar 31, 2020 |
| 10-K | Annual report | Apr 6, 2020 | Dec 31, 2019 |
| NT 10-K | Filing | Mar 30, 2020 | Dec 31, 2019 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Mar 24, 2020 | Mar 19, 2020 |
| 4 | Insider transaction | Feb 19, 2020 | Feb 17, 2020 |
| 4 | Insider transaction | Feb 19, 2020 | Feb 17, 2020 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jan 31, 2020 | Jan 28, 2020 |
| DEFR14C | Filing | Jan 3, 2020 | — |
| 4 | Insider transaction | Dec 13, 2019 | Dec 13, 2019 |
| 4 | Insider transaction | Dec 13, 2019 | Dec 13, 2019 |
| 4 | Insider transaction | Dec 13, 2019 | Nov 5, 2019 |
| DEF 14C | Information statement | Nov 22, 2019 | Nov 1, 2019 |
| 10-Q | Quarterly report | Nov 14, 2019 | Sep 30, 2019 |
| 4 | Insider transaction | Nov 5, 2019 | Nov 5, 2019 |
| PRE 14C | Filing | Nov 5, 2019 | Nov 5, 2019 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 16, 2019 | Oct 11, 2019 |
| DEF 14C | Information statement | Sep 13, 2019 | Aug 26, 2019 |
| 8-K |
Current report
Other events
|
Sep 9, 2019 | Sep 4, 2019 |
| PRE 14C | Filing | Aug 30, 2019 | Aug 30, 2019 |
| 10-Q | Quarterly report | Aug 13, 2019 | Jun 30, 2019 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jul 31, 2019 | Jul 24, 2019 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jul 8, 2019 | Jul 2, 2019 |
| 4 | Insider transaction | Jul 3, 2019 | Jun 30, 2019 |
| 4 | Insider transaction | Jul 3, 2019 | Jun 30, 2019 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CELZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Phoenix, AZ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1187953
- Former names
- JOLLEY MARKETING INC (until May 13, 2016)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.